Pioneering Pharma of the Future℠ .

Do you feel that? It’s the industry changing. And no one has a finger on the pulse of drug development like our fearless leader Ted Grasela. So we thought, hey, let’s give him an outlet to share his wisdom. And so the Cognigen blog was born. Check back here often for insightful articles, unique views on industry trends, and a whole lot more on the evolution of this critical field.

August 19, 2010

Not too complicated for words.

Increasing the transparency, speed, and reliability of information flow among researchers in integrated project teams is a critical step in improving research productivity.

July 1, 2010

A Drug Is Not a Jet Plane, or Is It?

The innovations of model-based drug development must be implemented with full attention paid to its effects on the upstream and downstream components of the larger enterprise.

April 28, 2010

Disambiguation

Disambiguation means to remove ambiguity. It seems to me that the smarter the people and the more complex the topic, the more disambiguation is necessary.

March 23, 2010

Origins of Pharma of the Future℠

The pharma industry has a critical need to establish model-based drug development. The Pharma of the Future℠ (PoF) program is a research initiative to support this important enterprise transformation. In this blog entry, we tell the story of the program that inspired PoF.

January 20, 2010

Intro to Pharma of the Future℠

The pharma industry has a critical need to establish model-based drug development. The Pharma of the Future℠ (PoF) program is a research initiative to support this important enterprise transformation.

November 17, 2009

An Uncommon Vignette?

Tired of late-stage development failures, the CEO of a pharmaceutical company decides to act on the promise of pharmacometrics. “Fix it,” he says to the head of clinical pharmacology, “I don’t care what it takes!”

October 27, 2009

Square Pegs in Round Holes?

A crusading scientist identifies a potential public health threat and uses the internet to get access to a cache of data from several studies. Sound like the plot of a new medical thriller?

September 11, 2009

Kerfuffle! (pt 3)

A kerfuffle is the polite term for a cascading series of errors that can be initiated by a seemingly innocuous event that then leads to other errors that seem to gain in severity and impact. Formalization of the pharmacometrics process, and the definition of process maps for the key tasks invoked in modeling and simulation activities, can prevent kerfuffles.

February 17, 2009

Kerfuffle! (pt 2)

A kerfuffle is the polite term for a cascading series of errors that can be initiated by a seemingly innocuous event that then leads to other errors that seem to gain in severity and impact. But where do kerfuffles come from and how do we prevent them from happening?

November 14, 2008

Beauty and the Beast?

Several large Pharma companies have announced interest in acquiring small biotech companies. Many Pharma companies have reduced or eliminated drug discovery efforts, and with stock prices back at 2003 levels, there certainly is a great deal of sense in these acquisitions. But finding another way to integrate these companies and their development portfolio also makes a great deal of sense.